These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 37578634)

  • 1. Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses.
    Blum SM; Rouhani SJ; Sullivan RJ
    Immunol Rev; 2023 Sep; 318(1):167-178. PubMed ID: 37578634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
    Bhatlapenumarthi V; Patwari A; Harb AJ
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis and evaluation of factors contributing to the occurrence of immune-related adverse events with immune checkpoint inhibitors.
    Nagase T; Shima O; Maruhana N; Miyazawa Y; Yoshino S; Sato J; Yamada H; Shinozaki K; Ikeda K
    Pharmazie; 2024 Aug; 79(7):163-168. PubMed ID: 39152557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
    Akamatsu H; Murakami E; Oyanagi J; Shibaki R; Kaki T; Takase E; Tanaka M; Harutani Y; Yamagata N; Okuda Y; Furuta K; Sugimoto T; Teraoka S; Hayata A; Tokudome N; Ozawa Y; Mori K; Koh Y; Yamamoto N
    Oncologist; 2020 Apr; 25(4):e679-e683. PubMed ID: 32297443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
    Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
    Front Immunol; 2021; 12():730320. PubMed ID: 34646270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatic immune-related adverse events induced by immune checkpoint inhibitors.
    Zhong H; Zhou J; Xu D; Zeng X
    Asia Pac J Clin Oncol; 2021 Jun; 17(3):178-185. PubMed ID: 32717098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma.
    Chen M; Ma P; Zhang Y; Wang D; Yu Z; Fu Y; Zhao X; Wang M; Zhuang G; Jing Y
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors.
    Jia XH; Geng LY; Jiang PP; Xu H; Nan KJ; Yao Y; Jiang LL; Sun H; Qin TJ; Guo H
    J Exp Clin Cancer Res; 2020 Dec; 39(1):284. PubMed ID: 33317597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of immune checkpoint inhibitor-related rheumatic adverse events.
    Zhou J; Wang H; Guo X; Wang Q; Duan L; Si X; Zhang L; Liu X; Li Y; Zhang W; Zhang L
    Thorac Cancer; 2020 Jan; 11(1):198-202. PubMed ID: 31762209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials.
    Xie T; Zhang Z; Qi C; Lu M; Zhang X; Li J; Shen L; Peng Z
    Oncologist; 2021 Dec; 26(12):e2239-e2246. PubMed ID: 34396642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
    Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
    Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral lymphocyte fluctuation as an indicator of severe immune-related adverse events in patients treated with immune checkpoint inhibitors.
    Haraguchi M; Nakao Y; Narita S; Matsumoto K; Fukushima M; Sasaki R; Honda T; Miuma S; Miyaaki H; Nakao K
    Cancer Med; 2023 May; 12(9):10636-10646. PubMed ID: 36934436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events.
    Kawahira M; Kanmura S; Mizuno K; Machida K; Ohtsuka T; Sato M; Enokida H; Yamashita M; Kanekura T; Arima S; Nakamura N; Sugiura T; Yoshimoto K; Kobayashi H; Ishitsuka K; Suzuki S; Ueno S; Ido A
    PLoS One; 2022; 17(4):e0267572. PubMed ID: 35482642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
    Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
    Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
    BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
    Matsuoka H; Hayashi T; Takigami K; Imaizumi K; Shiroki R; Ohmiya N; Sugiura K; Kawada K; Sawaki A; Maeda K; Ando Y; Uyama I
    BMC Cancer; 2020 Jul; 20(1):656. PubMed ID: 32664888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
    Ruf T; Kramer R; Forschner A; Leiter U; Meier F; Reinhardt L; Dücker P; Ertl C; Tomsitz D; Tietze JK; Gutzmer R; Dabrowski E; Zimmer L; Gesierich A; Zierold S; French LE; Eigentler T; Amaral T; Heinzerling L
    Eur J Cancer; 2024 May; 203():114028. PubMed ID: 38652976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity profiles of immune checkpoint inhibitors in nervous system cancer: a comprehensive disproportionality analysis using FDA adverse event reporting system.
    Liu R; Zhao H; Lu Z; Zeng L; Shi H; Wu L; Wang J; Zhong F; Liu C; Zhang Y; Qiu Z
    Clin Exp Med; 2024 Sep; 24(1):216. PubMed ID: 39249163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.